Q&A: FDA’s LDT Inaction Catches Veteran Attorney Off-Guard
Executive Summary
Industry experts expected the US FDA to swiftly reverse a Trump-administration policy blocking oversight of lab-developed tests. Its inaction has one former agency attorney wondering why.